Skip to main content
SpringerLink
Log in
Book cover

Non-Myeloablative Allogeneic Transplantation pp 51–77Cite as

Mobilization of Allogeneic Peripheral Blood Progenitor Cells

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 110))

Abstract

It is possible to reliably obtain sufficient PBSC from most normal donors to perform allogeneic transplantation. The mobilization regimen, usually administration of a single daily dose of G-CSF at 7.5 to 10 μg/kg subcutaneously for 4 to 6 days, is tolerable with acceptable side effects. However, there is wide variability among individuals with respect to the extent of mobilization achieved by the regimen and the optimal timing of apheresis. Studies suggest that the likelihood of obtaining an adequate harvest of CD34+ cells, as defined locally may be enhanced by employing higher doses or different schedules of G-CSF, monitoring the mobilization and/or collection of PBPC, and using apheresis procedures processing 2 or more times blood volume. However, an optimal regimen for mobilization and harvesting for all donors has not yet been identified and a small percentage of donors may not mobilize adequately with G-CSF. Alternative regimens employing combinations of G-CSF and GM-CSF are available that may prove useful in such cases and novel cytokines that are even more effective than G-CSF in mobilizing stem cells are eagerly awaited. Based on currently available experience with normal donors, the short-term safety of G-CSF appears to be acceptable, however there exist several scenarios in which marrow harvesting may be preferable to G-CSF mobilization and apheresis collection of PBPC.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematology/Oncology Clinics of North America 1999;13 (5): 1041–57

    Article  PubMed  CAS  Google Scholar 

  2. Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology 1999;13 (5): 621–8; discussion 631, 63.

    PubMed  CAS  Google Scholar 

  3. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graftversus-malignancy. Current Opinion in Oncology 1999;11(2): 8795.

    Article  Google Scholar 

  4. Champlin R, Khouri I, Giralt S. Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs. -malignancy as treatment for malignant diseases. Journal of Clinical Apheresis 1999;14(1): 45–9.

    Article  PubMed  CAS  Google Scholar 

  5. Champlin R, Khouri I, Giralt S. Graft-vs. -malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. Pediatric Transplantation 1999;3 (Suppl 11): 52–8.

    Article  PubMed  Google Scholar 

  6. Giralt S, Khouri I, Champlin R. Non myeloablative “mini transplants” Cancer Treatment and Research 1999;101(2A): 97–108.

    Article  PubMed  CAS  Google Scholar 

  7. Nagler A, Ackerstein A, Kapelushnik J, Or R, Naparstek E, Slavin S. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplantation 1999;24(3): 339–42.

    Article  PubMed  CAS  Google Scholar 

  8. Varadi G, Or R, Kapelushnik J, Naparstek E, Nagler A, Brautbar C, et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leukemia and Lymphoma 1999;34(12): 185–90.

    PubMed  CAS  Google Scholar 

  9. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic Xperipheral blood stem cell transplantation using a fludarabinebased low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplantation 2000;25(10): 1021–8.

    Article  PubMed  CAS  Google Scholar 

  10. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000;85(3): 304–13.

    PubMed  CAS  Google Scholar 

  11. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Experimental Hematology 2000;28(7): 853–7.

    Article  PubMed  CAS  Google Scholar 

  12. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Miniallografts: ongoing trials in humans [editorial]. Bone Marrow Transplantation 2000;25(4): 345–50.

    Article  PubMed  CAS  Google Scholar 

  13. Theilgaard-Mönch K, Raaschou-Jensen K, Andersen H, Russell CA, Vindelov L, Jacobsen N, et al. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. Bone Marrow Transplantation 1999;23(3): 243–9.

    Article  PubMed  Google Scholar 

  14. Reisner Y, Bachar-Lustig E, Li HW, Aversa F, Velardi A, Martelli MF. The role of megadose CD34 progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Annals of the New York Academy of Sciences 1999;872(5): 336–48;

    Article  PubMed  CAS  Google Scholar 

  15. Reisner Y, Martelli MF. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunology Today 1999;20(8): 343–7.

    Article  PubMed  CAS  Google Scholar 

  16. Reisner Y, Martelli MF. Transplantation tolerance induced by “mega dose” CD34+ cell transplants. Experimental Hematology 2000;28(2): 119–27.

    Article  PubMed  CAS  Google Scholar 

  17. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996;88(7): 2794–800.

    PubMed  CAS  Google Scholar 

  18. Russell JA, Larratt L, Brown C, Turner AR, Chaudhry A, Booth K, et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplantation 1999;24(11): 1177–83.

    Article  PubMed  CAS  Google Scholar 

  19. Snowden JA, Nivison-Smith I, Atkinson K, Fay K, Concannon A, Dodds A, et al. Allogeneic PBPC transplantation: an effect on incidence and distribution of chronic graft-versus-host disease without long-term survival benefit? [letter]. Bone Marrow Transplantation 2000;25(1): 119–20.

    Article  PubMed  CAS  Google Scholar 

  20. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Löffler H, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. British Journal of Haematology 1994;87(3): 609–13.

    Article  PubMed  CAS  Google Scholar 

  21. Höglund M, Smedmyr B, Simonsson B, Tötterman T, Bengtsson M. Dose-dependent mobilization of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplantation 1996;18(1): 19–27.

    PubMed  Google Scholar 

  22. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW, et al. Optimizing dose and scheduling of flgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers [see comments]. Blood 1995;86(12): 4437–45.

    PubMed  CAS  Google Scholar 

  23. Luider J, Brown C, Selinger S, Quinlan D, Karlsson L, Ruether D, et al. Factors influencing yields of progenitor cells for allogeneic transplantation: optimization of G-CSF dose, day of collection, and duration of leukapheresis. Journal of Hematotherapy 1997;6(6): 575–80.

    Article  PubMed  CAS  Google Scholar 

  24. Urbano-Ispizua A, Solano C, Brunet S, Hernández F, Sanz G, Alegre A, et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group. Bone Marrow Transplantation 1996;18(1): 35–40.

    PubMed  CAS  Google Scholar 

  25. Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, et al. Treatment of normal individuals with granulocyte-colonystimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells [see comments]. Transfusion 1996;36(7): 601–10.

    Article  PubMed  CAS  Google Scholar 

  26. Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M, et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. Journal of Clinical Oncology 1997;15(9): 3067–74.

    PubMed  CAS  Google Scholar 

  27. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. Journal of Clinical Oncology 1999;17(7): 2160–72.

    PubMed  CAS  Google Scholar 

  28. Martínez C, Urbano-Ispizua A, Marín P, Merino A, Rovira M, Carreras E, et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplantation 1999;24(12): 1273–8.

    Article  PubMed  Google Scholar 

  29. Waller CF, Bertz H, Wenger MK, Fetscher S, Hardung M, Engelhardt M, et al. Mobilization of peripheral blood progenitor cell for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplantation 1996;18(2): 279–83.

    PubMed  CAS  Google Scholar 

  30. Majolino I, Scimé R, Vasta S, Cavallaro AM, Fiandaca T, Indovina A, et al. Mobilization and collection of PBSC in healthy donors: comparison between two schemes of rhG-CSF administration. European Journal of Haematology 1996;57(3): 214–21.

    Article  PubMed  CAS  Google Scholar 

  31. Anderlini P, Przepiorka D, Huh Y, Lauppe J, Miller P, Sundberg J, et al. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. British Journal of Haematology 1996;93(4): 940–2.

    Article  PubMed  CAS  Google Scholar 

  32. Anderlini P, Przepiorka D, Seong D, Champlin R, Körbling M. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. British Journal of Haematology 1996;94(1): 155–8.

    Article  PubMed  CAS  Google Scholar 

  33. Pollmächer T, Korth C, Mullington J, Schreiber W, Sauer J, Vedder H, et al. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996;87(3): 900–5.

    PubMed  Google Scholar 

  34. Yano T, Katayama Y, Sunami K, Deguchi S, Nawa Y, Hiramatsu Y, et al. G-CSF-induced mobilization of peripheral blood stem cells for allografting: comparative study of daily single versus divided dose of G-CSF. International Journal of Hematology 1997;66(2): 16978.

    Google Scholar 

  35. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. British Journal of Haematology 2000;109(4): 770–2.

    Article  PubMed  CAS  Google Scholar 

  36. Arbona C, Prosper F, Benet I, Mena F, Solano C, Garcia-Conde J. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplantation 1998;22(1): 39–45.

    Article  PubMed  CAS  Google Scholar 

  37. Sato N, Sawada K, Takahashi TA, Mogi Y, Asano S, Koike T, et al. A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers. Experimental Hematology 1994;22(10): 97–38.

    Google Scholar 

  38. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994;84(11): 3885–94.

    PubMed  Google Scholar 

  39. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995;85(1): 275–82.

    PubMed  CAS  Google Scholar 

  40. Matsunaga T, Sakamaki S, Kohgo Y, Ohi S, Hirayama Y, Niitsu Y. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplantation 1993;11(2): 103–8.

    PubMed  CAS  Google Scholar 

  41. Zaino EC. Blood counts in the nonagenarian. New York State Journal of Medicine 1981;81(8): 1199–200.

    PubMed  CAS  Google Scholar 

  42. Lipschitz DA, Udupa KB, Milton KY, Thompson CO. Effect of age on hematopoiesis in man. Blood 1984;63(3): 502–9.

    PubMed  CAS  Google Scholar 

  43. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, et al. Marrow harvesting from normal donors. Blood 1984;64(3): 630–4.

    PubMed  CAS  Google Scholar 

  44. Chatta GS, Andrews RG, Rodger E, Schrag M, Hammond WP, Dale DC. Hematopoietic progenitors and aging: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. Journal of Gerontology 1993;48(5): M207–12.

    PubMed  CAS  Google Scholar 

  45. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplantation 1994;14(6): 913–8.

    PubMed  CAS  Google Scholar 

  46. Haas R, Möhle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83(12): 3787–94.

    PubMed  CAS  Google Scholar 

  47. Kotasek D, Shepherd KM, Sage RE, Dale BM, Norman JE, Charles P, et al. Factors affecting blood stem cell collections following hight dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplantation 1992;9(1): 11–7.

    PubMed  CAS  Google Scholar 

  48. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 1995;13(10): 2547–55.

    PubMed  CAS  Google Scholar 

  49. Miflin G, Charley C, Stainer C, Anderson S, Hunter A, Russell N. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. British Journal of Haematology 1996;95(2): 345–8.

    Article  PubMed  CAS  Google Scholar 

  50. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994;84(9): 2923–9.

    PubMed  CAS  Google Scholar 

  51. Kawano Y, Takaue Y, Watanabe T, Abe T, Okamoto Y, Iwai A, et al. Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. Cancer Research 1999;59(14): 3321–4.

    PubMed  CAS  Google Scholar 

  52. Anderlini P, Przepiorka D, Seong C, Smith TL, Huh YO, Lauppe J, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997;37(5): 507–12.

    Article  PubMed  CAS  Google Scholar 

  53. Wiesneth M, Schreiner T, Friedrich W, Bunjes D, Duncker C, Krug E, et al. Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Bone Marrow Transplantation 1998;21 (Suppl 6): S21–S4.

    PubMed  Google Scholar 

  54. Bishop MR, Tarantolo SR, Jackson JD, Anderson JR, SchmitPokorny K, Zacharias D, et al. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. Journal of Clinical Oncology 1997;15(4): 1601–7.

    PubMed  CAS  Google Scholar 

  55. Anderlini P, Przepiorka D, Lauppe J, Seong D, Giralt S, Champlin R, et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. British Journal of Haematology 1997;97(2): 485–7.

    Article  PubMed  CAS  Google Scholar 

  56. Roberts AW, Begley CG, Grigg AP, Basser RL. Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone? [letter; comment]. Blood 1995;86(6): 2451.

    Google Scholar 

  57. Passos-Coelho JL, Braine HG, Davis JM, Huelskamp AM, Schepers KG, Ohly K, et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. Journal of Clinical Oncology 1995;13(3): 705–14.

    PubMed  CAS  Google Scholar 

  58. Carlo-Stella C, Cesana C, Regazzi E, Falzetti F, Aversa F, Rizzoli V, et al. Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor. Experimental Hematology 2000;28(2): 21624.

    Article  Google Scholar 

  59. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin’s lymphoma patients--results of a phase I/II trial. Blood 1997;89(9): 3136–47.

    PubMed  CAS  Google Scholar 

  60. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999;93(8): 2491–501.

    PubMed  CAS  Google Scholar 

  61. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997;90(8): 2939–51.

    PubMed  CAS  Google Scholar 

  62. Huhn RD, Yurkow EJ, Tushinski R, Clarke L, Sturgill MG, Hoffman R, et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Experimental Hematology 1996;24(7): 83947.

    Google Scholar 

  63. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer [published erratum appears in Blood 1997 Sep 15;90(6): 2513]. Blood 1997;89(9): 3118–28.

    PubMed  CAS  Google Scholar 

  64. Papayannopoulou T, Nakamoto B, Andrews RG, Lyman SD, Lee MY. In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 1997;90(2): 620–9.

    PubMed  CAS  Google Scholar 

  65. Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998;91(7): 2231–9.

    PubMed  CAS  Google Scholar 

  66. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA4 integrin mobilize longterm repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997;90(12): 4779–88.

    PubMed  CAS  Google Scholar 

  67. Corringham RE, Ho AD. Rapid and sustained allogeneic transplantation using immunoselected CD34(+)-selected peripheral blood progenitor cells mobilized by recombinant granulocyte-and granulocyte-macrophage colony-stimulating factors [letter]. Blood 1995;86(5): 2052–4.

    PubMed  CAS  Google Scholar 

  68. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage-and granulocytecolony-stimulating factors. Transfusion 1999;39(1): 39–47.

    Article  PubMed  CAS  Google Scholar 

  69. Ho AD, Young D, Maruyama M, Corringham RE, Mason JR, Thompson P, et al. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. Experimental Hematology 1996;24(13): 1460–8.

    PubMed  CAS  Google Scholar 

  70. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocytecolony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures [see comments] [published erratum appears in Transfusion 1997 Jan;37(1): 109]. Transfusion 1996;36(7): 5905.

    Article  Google Scholar 

  71. Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplantation 1999;24(10): 1065–71.

    Article  PubMed  CAS  Google Scholar 

  72. Gudi R, Krishnamurthy M, Pachter BR. Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain [letter] [see comments]. Annals of Internal Medicine 1995;123(3): 236–7.

    PubMed  CAS  Google Scholar 

  73. Stroncek DF, Clay ME, Smith J, Ilstrup S, Oldham F, McCullough J. Changes in blood counts after the administration of granulocytecolony-stimulating factor and the collection of peripheral blood stem cells from healthy donors [see comments]. Transfusion 1996;36(7): 596–600.

    Article  PubMed  CAS  Google Scholar 

  74. Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al. Allogeneic blood stem cell transplantation: considerations for donors [editorial]. Blood 1997;90(3): 903–8.

    PubMed  CAS  Google Scholar 

  75. Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997;37(2): 182–7.

    Article  PubMed  CAS  Google Scholar 

  76. Weaver CH, Buckner CD, Longin K, Appelbaum FR, Rowley S, Lilleby K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993;82(7): 1981–4.

    PubMed  CAS  Google Scholar 

  77. Gabrilove JL, Jakubowski A, Fain K, Grous J, Scher H, Sternberg C, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. Journal of Clinical Investigation 1988;82(4): 1454–61.

    Article  PubMed  CAS  Google Scholar 

  78. Sica S, Rutella S, Di Mario A, Salutari P, Rumi C, Ortu la Barbera E, et al. rhG-CSF in healthy donors: mobilization of peripheral hemopoietic progenitors and effect on peripheral blood leukocytes. Journal of Hematotherapy 1996;5(4): 391–7.

    Article  PubMed  CAS  Google Scholar 

  79. Hillyer CD, Tiegerman KO, Berkman EM. Increase in circulating colony-forming units-granulocyte-macrophage during large-volume leukapheresis: evaluation of a new cell separator. Transfusion 1991;31(4): 327–32.

    Article  PubMed  CAS  Google Scholar 

  80. Malachowski ME, Comenzo RL, Hillyer CD, Tiegerman KO, Berkman EM. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992;32(8): 732–5.

    Article  PubMed  CAS  Google Scholar 

  81. Lasky LC, Lin A, Kahn RA, McCullough J. Donor platelet response and product quality assurance in plateletpheresis. Transfusion 1981;21(3): 247–60.

    Article  PubMed  CAS  Google Scholar 

  82. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, et al. The effects of daily recombinant human granulocytecolony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis [see comments]. Blood 1993;81(7): 1883–8.

    PubMed  CAS  Google Scholar 

  83. Rogers RL, Johnson H, Ludwig G, Winegarden D, Randels MJ, Strauss RG. Efficacy and safety of plateletpheresis by donors with low-normal platelet counts. Journal of Clinical Apheresis 1995;10(4): 194–7.

    Article  PubMed  CAS  Google Scholar 

  84. Gutensohn K, Maerz M, Kuehnl P. Alteration of platelet-associated membrane glycoproteins during extracorporeal apheresis of peripheral blood progenitor cells. Journal of Hematotherapy 1997;6(4): 315–21.

    Article  PubMed  CAS  Google Scholar 

  85. Okamoto S, Ishida A, Wakui M, Tanosaki R, Oda A, Ikeda Y. Prolonged thrombocytopenia after administration of granulocyte colony-stimulating factor and leukapheresis in a donor for allogeneic peripheral blood stem cell transplantation [letter]. Bone Marrow Transplantation 1996;18(2): 482–3.

    PubMed  CAS  Google Scholar 

  86. Ordemann R, Hölig K, Wagner K, Rautenberg U, Bornhäuser M, Kroschinsky F, et al. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. Bone Marrow Transplantation 1998;21 (Suppl 3): S25–8.

    PubMed  Google Scholar 

  87. Link H, Arseniev L, Bähre O, Kadar JG, Diedrich H, Poliwoda H. Transplantation of allogeneic CD34+ blood cells. Blood 1996;87(11): 4903–9.

    PubMed  CAS  Google Scholar 

  88. Bensinger WI, Buckner CD, Shannon-Dorcy K, Rowley S, Appelbaum FR, Benyunes M, et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996;88(11): 4132–8.

    PubMed  CAS  Google Scholar 

  89. Avenarius HJ, Freund M, Kleine HD, Heussner P, Poliwoda H. Granulocyte colony-stimulating factor enhances the expression of CD62 on platelets in vivo. International Journal of Hematology 1993;58(3): 189–96.

    PubMed  CAS  Google Scholar 

  90. Kuroiwa M, Okamura T, Kanaji T, Okamura S, Harada M, Niho Y. Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. International Journal of Hematology 1996;63(4): 311–6.

    Article  PubMed  CAS  Google Scholar 

  91. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony stimulating factor on platelets. Journal of Clinical Investigation 1993;91(4): 1310–3.

    Article  PubMed  CAS  Google Scholar 

  92. Conti JA, Scher HI. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer 1992;70(11): 2699–702.

    Article  PubMed  CAS  Google Scholar 

  93. Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K. Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. British Journal of Haematology 1996;94(2): 413–6.

    Article  PubMed  CAS  Google Scholar 

  94. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. Journal of Clinical Apheresis 1994;9(2): 130–4.

    Article  PubMed  CAS  Google Scholar 

  95. Körbling M, Anderlini P, Durett A, Maadani F, Bojko P, Seong D, et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplantation 1996;18(6): 1073–9.

    PubMed  Google Scholar 

  96. Kadar JG, Arseniev L, Schnitger K, Südmeier I, Zaki M, Battmer K, et al. Technical and safety aspects of blood and marrow transplantation using G-CSF mobilized family donors. Transfusion Science 1996;17(4): 611–8.

    PubMed  CAS  Google Scholar 

  97. Becker PS, Wagle M, Matous S, Swanson RS, Pihan G, Lowry PA, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells [published erratum appears in Biol Blood Marrow Transplant 1997 Jun;3(2): 108] [see comments]. Biology of Blood and Marrow Transplantation 1997;3(1): 45–9.

    PubMed  CAS  Google Scholar 

  98. Huestis DW. Adverse effects in donors and patients subjected to hemapheresis. Journal of Clinical Apheresis 1984;2(1): 81–90.

    Article  PubMed  CAS  Google Scholar 

  99. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor [see comments]. Blood 1995;85(6): 1655–8.

    PubMed  CAS  Google Scholar 

  100. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocytecolony-stimulating factor) [see comments]. Blood 1995;85(6): 1666–72.

    PubMed  CAS  Google Scholar 

  101. Russell JA, Bowen T, Brown C, Luider J, Ruether JD, Stewart D, et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplantation 1996;18(3): 501–5.

    PubMed  CAS  Google Scholar 

  102. Goldberg SL, Mangan KF, Klumpp TR, Macdonald JS, Thomas C, Mullaney MT, et al. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. Journal of Hematotherapy 1995;4(2): 85–90.

    Article  PubMed  CAS  Google Scholar 

  103. Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F, et al. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplantation 1998;22(11): 1035–41.

    Article  PubMed  CAS  Google Scholar 

  104. Cho SG, Park YM, Moon H, Kim KM, Bae SS, Kim GB, et al. Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer. Journal of Korean Medical Science 1998;13(6): 685–8.

    PubMed  CAS  Google Scholar 

  105. Parkkali T, Volin L, Sirén MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplantation 1996;17(3): 433–4.

    PubMed  CAS  Google Scholar 

  106. Anderlini P, Przepiorka D, Champlin R, Körbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996;88(8): 2819–25.

    PubMed  CAS  Google Scholar 

  107. Caspar CB, Seger RA, Burger J, Gmür J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor [see comments]. Blood 1993;81(11): 2866–71.

    PubMed  CAS  Google Scholar 

  108. Harada M, Nagafuji K, Fujisaki T, Kubota A, Mizuno S, Takenaka K, et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. Journal of Hematotherapy 1996;5(1): 63–71.

    Article  PubMed  CAS  Google Scholar 

  109. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplantation 2000;25(1): 85–9.

    Article  PubMed  CAS  Google Scholar 

  110. Anderlini P, Lauppe J, Przepiorka D, Seong D, Champlin R, Körbling M. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. British Journal of Haematology 1997;96(2): 415–7.

    Article  PubMed  CAS  Google Scholar 

  111. Stroncek DF, Clay ME, Herr G, Smith J, Ilstrup S, McCullough J. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997;37(3): 304–8.

    Article  PubMed  CAS  Google Scholar 

  112. Matsushita K, Arima N, Ohtsubo H, Fujiwara H, Hidaka S, Kukita T, et al. Granulocyte-colony stimulating factor-induced proliferation of primary adult 1-cell leukaemia cells. British Journal of Haematology 1997;96(4): 715–23.

    Article  PubMed  CAS  Google Scholar 

  113. Morstyn G, Lieschke GJ, Sheridan W, Layton J, Cebon J, Fox RM. Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. Seminars in Hematology 1989;26( Suppl 2): 9–13.

    PubMed  CAS  Google Scholar 

  114. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990;76(10): 1962–4.

    PubMed  CAS  Google Scholar 

  115. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y. Haematological study of healthy volunteers 5 years after G-CSF [letter]. Lancet 1995;346(8987): 1432–3.

    Article  PubMed  CAS  Google Scholar 

  116. Imashuku S, Hibi S, Nakajima F, Mitsui T, Yokoyama S, Kojima S, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor [letter]. Blood 1994;84(7): 2380–1.

    PubMed  CAS  Google Scholar 

  117. Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000;96(2): 429–36.

    PubMed  CAS  Google Scholar 

  118. Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF [letter]. New England Journal of Medicine 1992;326(19): 1294–5.

    Article  PubMed  CAS  Google Scholar 

  119. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. British Journal of Haematology 1994;88(4): 723–30.

    Article  PubMed  CAS  Google Scholar 

  120. Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulatingfactor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia [see comments]. New England Journal of Medicine 1995;333(8): 487–93.

    Article  PubMed  CAS  Google Scholar 

  121. Imashuku S, Hibi S, Kataoka-Morimoto Y, Yoshihara T, Ikushima S, Morioka Y, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. British Journal of Haematology 1995;89(1): 188–90.

    Article  PubMed  CAS  Google Scholar 

  122. Gilman PA, Jackson DP, Guild HG. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970;36(5): 576–85.

    PubMed  CAS  Google Scholar 

  123. de Planque MM, Bacigalupo A, Würsch A, Hows JM, Devergie A, Frickhofen N, et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). British Journal of Haematology 1989;73(1): 121–6.

    Article  PubMed  Google Scholar 

  124. Hasenclever D, Sextro M. Safety of Al1oPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplantation 1996;17 Suppl 2(1): S28–S30.

    PubMed  Google Scholar 

  125. Bortin MM, D’Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood 1987;70(1): 227–32.

    PubMed  CAS  Google Scholar 

  126. Gluckman E, Socie G, Guivarch C, al e. The long time forgotten HLA identical bone marrow donor: result of a survey on 818 patients [abstract]. Blood 1996;88 (suppl 1): 612.

    Google Scholar 

Download references

Authors
  1. Ping Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Blood and Marrow Transplantation Division, University of California, San Diego, USA

    Asad Bashey M.D., Ph.D.  & Edward D. Ball M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Law, P., Lane, T.A. (2002). Mobilization of Allogeneic Peripheral Blood Progenitor Cells. In: Bashey, A., Ball, E.D. (eds) Non-Myeloablative Allogeneic Transplantation. Cancer Treatment and Research, vol 110. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0919-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0919-6_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5304-1

  • Online ISBN: 978-1-4615-0919-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation